Quick Answer
CRISPR Therapeutics AG reported Stockholders Equity of $1.92 billion for the year ending 2025.
- CRISPR Therapeutics AG showed a decrease of -0.5% in Stockholders Equity from 2024 to 2025.
- This data is from CRISPR Therapeutics AG's annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2016: -$62.48 million | Q1 2017: $215.18 million | Q2 2017: $197.80 million | Q3 2017: $178.96 million | Q1 2018: $290.34 million | Q2 2018: $265.15 million | Q3 2018: $417.31 million | Q1 2019: $379.81 million | Q2 2019: $367.68 million | Q3 2019: $591.88 million | Q1 2020: $886.10 million | Q2 2020: $910.67 million | Q3 2020: $1.34 billion | Q1 2021: $1.81 billion | Q2 2021: $2.60 billion | Q3 2021: $2.51 billion | Q1 2022: $2.24 billion | Q2 2022: $2.09 billion | Q3 2022: $1.95 billion | Q1 2023: $1.85 billion | Q2 2023: $1.82 billion | Q3 2023: $1.73 billion | Q1 2024: $2.08 billion | Q2 2024: $1.98 billion | Q3 2024: $1.94 billion | Q1 2025: $1.83 billion | Q2 2025: $1.71 billion | Q3 2025: $1.92 billion.
- Over the full 11 years of available data (2015 to 2025), CRISPR Therapeutics AG's Stockholders Equity has grown by 6,704.8%.
- Historical annual values: Fiscal year 2025: $1.92 billion | Fiscal year 2024: $1.93 billion | Fiscal year 2023: $1.88 billion | Fiscal year 2022: $1.88 billion | Fiscal year 2021: $2.40 billion | Fiscal year 2020: $1.66 billion | Fiscal year 2019: $939.43 million | Fiscal year 2018: $392.20 million | Fiscal year 2017: $187.83 million | Fiscal year 2016: $232.85 million | Fiscal year 2015: -$29.10 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: